Litcius/Paper detail

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Tibor Csőszi, Ihor Vynnychenko, Oleksandr Goloborodko, Alexander Luft, А. Л. Акопов, Alex Martínez‐Martí, Hirotsugu Kenmotsu, Yuh‐Min Chen, Antonio Chella, Shunichi Sugawara, David Voong, Fan Wu, Jing Yi, Yu Deng, Mark L. McCleland, Elizabeth Bennett, Barbara J. Gitlitz, Heather A. Wakelee

2021The Lancet1,481 citationsDOI

Topics & Concepts

AtezolizumabMedicineAdjuvantOncologyAdjuvant chemotherapyStage (stratigraphy)Lung cancerInternal medicineChemotherapyOpen labelCancerClinical trialImmunotherapyBreast cancerPembrolizumabPaleontologyBiologyLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial | Litcius